RECRUITING

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Description

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Conditions

Glaucoma
Talk to us

Related Conditions:

Glaucoma

Study Overview

On this page

Study Details

Study overview

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Condition
Glaucoma
Intervention / Treatment

-

Contacts and Locations

Grand Junction

Glaukos Investigative Site, Grand Junction, Colorado, United States, 81501

Oklahoma City

Glaukos Investigative Site, Oklahoma City, Oklahoma, United States, 73112

El Paso

Glaukos Clinical Site, El Paso, Texas, United States, 79922

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of OAG (i.e., primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye
  • * Prior incisional glaucoma surgery or ALT or prior MIGS surgery (e.g., implantable stents/devices, goniotomy, canal dilation procedures)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Glaukos Corporation,

Luis G. Vargas, MD, STUDY_CHAIR, Glaukos Corporation

Study Record Dates

2032-03